Gelesis
Financials
Estimates*
| EUR | 2017 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 11.8m | - | 10.2m | 23.4m | 46.7m |
| % growth | - | - | - | 130 % | 99 % |
| EBITDA | - | - | (73.2m) | (104m) | - |
| % EBITDA margin | - | - | (720 %) | (443 %) | - |
| Profit | - | - | (85.2m) | (51.9m) | - |
| % profit margin | - | - | (838 %) | (222 %) | - |
| EV / revenue | - | - | 34.1x | 3.0x | - |
| EV / EBITDA | - | - | -4.7x | -0.7x | - |
| R&D budget | - | - | 11.7m | 16.9m | - |
| R&D % of revenue | - | - | 115 % | 72 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $500k | Series A | |
$16.0m | Series B | ||
$1.0m | Grant | ||
| N/A | $2.6m | Seed | |
| N/A | $12.0m | Series E | |
$22.0m | Growth Equity VC | ||
$31.5m | Growth Equity VC | ||
| N/A | $3.1m | Grant | |
$30.0m | Growth Equity VC | ||
| N/A | $10.6m | Grant | |
$84.0m | Growth Equity VC | ||
N/A | - | ||
$240m Valuation: $1.0b | SPAC IPO | ||
$100m Valuation: $1.0b | SPAC Private Placement | ||
| Total Funding | $313m | ||
Recent News about Gelesis
EditGelesis is a biotechnology company focused on developing innovative therapies for gastrointestinal (GI) related chronic diseases. The company's proprietary platform features the first and only superabsorbent hydrogel made exclusively from naturally derived building blocks. Gelesis primarily serves adults who are overweight or obese, with a Body Mass Index (BMI) of 25 to 40, by offering products like PLENITY, which aids in weight management when combined with diet and exercise. The company operates in the healthcare and biotechnology market, targeting conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Type 2 diabetes, and Chronic Idiopathic Constipation (CIC). Gelesis generates revenue through the sale of its hydrogel-based therapies and continues to expand its pipeline of potential treatments for various GI-related conditions.
Keywords: biotechnology, hydrogel, gastrointestinal, obesity, weight management, chronic diseases, NAFLD, NASH, Type 2 diabetes, CIC.